Form 4: AtriCure CSO Sells 2,500 Shares

AtriCure's Chief Scientific Officer, Vinayak Doraiswamy, sold 2,500 shares of common stock for $36.58 per share.

Summary

• Vinayak Doraiswamy, Chief Scientific Officer of AtriCure, Inc. (ATRC), reported a sale of company common stock.
• The transaction involved the disposition of 2,500 shares of AtriCure common stock.
• The shares were sold at a price of $36.58 per share.
• Following this transaction, Mr. Doraiswamy beneficially owns 71,872 shares of AtriCure common stock.
• The reported transaction date is August 5, 2025, with the filing date being August 7, 2025.

Sentiment

Score: 3

Explanation: Insider selling, especially when not explicitly part of a 10b5-1 plan, can be perceived as a negative signal regarding management's confidence in the company's short-term prospects.

Negatives

• Chief Scientific Officer Vinayak Doraiswamy sold 2,500 shares of AtriCure common stock.
• Insider selling, especially when not explicitly part of a pre-arranged 10b5-1 trading plan, can sometimes be interpreted as a lack of confidence in the company's near-term prospects.

Risks

• Insider selling by a key executive may lead to negative market perception regarding the company's future performance.

Future Outlook

This filing, a Form 4, does not provide forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report (Form 4) provides specific details on a single executive's stock sale and does not offer broader industry context or trends.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a negative signal, potentially impacting stock price perception.

Key Dates

Recommendation

The sale of shares by a key executive, while not necessarily indicative of fundamental issues, can be perceived negatively by the market. Without additional context on the reason for the sale (e.g., personal financial planning vs. lack of confidence), a 'hold' recommendation is prudent to observe further developments and broader market trends for AtriCure.

Keywords

AtriCure, ATRC, insider trading, Form 4, stock sale, Vinayak Doraiswamy, Chief Scientific Officer, medical devices, healthcare